Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two significant stock price drops after the European Medicines Agency (EMA) twice rejected Omeros's drug narsoplimab for treating TA-TMA. The first rejection in June 2026 caused a nearly 20% stock fall, and a second negative opinion in October 2026 led to another nearly 14% drop. The investigation focuses on whether Omeros and its executives engaged in unlawful practices related to these announcements. Investors affected by these events are encouraged to contact the law firm for potential class action participation.
Omeros Corporation news is the subject, with Pluang market data providing context. For readers following health-sector stocks, 124 of 150 US stocks rose and 26 fell on October 21, 2026, at 03:11 WIB. Notable movers include LQDA at USD 36.53 (+7.03%, 81% Sell / 19% Buy), MRNA at USD 242.45 (+6.86%, 40% Sell / 60% Buy), and DFTX at USD 35.19 (+6.73%).
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
